Resources and Tools

Take advantage of the wide variety of resources that CSL Behring offers. Order educational materials about von Willebrand disease (VWD), access an award-winning website on VWD, or register for e-mail updates—and receive a book about VWD, with our compliments.

Request More Information
Sign up for e-mail updates and stay up-to-date on the latest news and research on von Willebrand disease (VWD) and Humate-P. Register now and you will receive the book, A Guide to Living With von Willebrand Disease. This book provides valuable information on living with the disease, and was written by a nurse who has VWD.

Patient Education Materials
For patients or parents, download or print helpful tools like a bleeding journal, or read an excerpt from A Guide to Living With von Willebrand Disease—the first book-length resource about VWD.

AllAboutBleeding-US.com
Access a Web site dedicated to increasing awareness about Bleeding Disorders, von Willebrand Disease (VWD), Hemophilia and other rare bleeding disorders.

Glossary of Terms
Just what is vasoconstriction? Learn key terms related to VWD here

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.